In a preclinical study, diabetic mice were given an every-other-day intraperitoneal injection of syringin (5 mg/kg. In another study, mice with cardiac hypertrophy were gavaged with syringin at doses of 50 mg/kg body weight (L-syringin) or 100 mg/kg body weight (syringin) for 7 weeks.

Murine RAW264.7 macrophages (10(6) cells/ml) were stimulated by LPS (1 ug/ml) in presence of syringin at concentrations of 62.5, 125, 250, 500, 1000 uM for 6 (TNF-alpha production assay) or 24 h (NO production assay). To study the effect of syringin on CD4+­T lymphocyte proliferation, splenocytes (5*10(6) cells/mL) were incubated with various concentrations of the drug (62.5, 125, 250, 500, 1000 uM) in the presence of Con A (1ug/ml) for 48 h. In order to test the effect of syringin on CTLL-2 proliferation stimulated by 25 IU/ml of IL-2, the cells (5*10(5) cells/mL) were incubated with the same range of concentrations of syringin in the presence of 25 IU/mL of IL-2 for 48 h.